• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dependency and health utilities in stroke: Data to inform cost-effectiveness analyses.中风中的依赖性与健康效用:为成本效益分析提供信息的数据。
Eur Stroke J. 2017 Mar;2(1):70-76. doi: 10.1177/2396987316683780. Epub 2017 Mar 1.
2
How well do standard stroke outcome measures reflect quality of life? A retrospective analysis of clinical trial data.标准卒中结局测量指标在多大程度上反映了生活质量?临床试验数据的回顾性分析。
Stroke. 2013 Nov;44(11):3161-5. doi: 10.1161/STROKEAHA.113.001126. Epub 2013 Sep 19.
3
Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1).缺血性中风的红外激光疗法:一种新的治疗策略:神经治疗有效性和安全性试验-1(NEST-1)的结果
Stroke. 2007 Jun;38(6):1843-9. doi: 10.1161/STROKEAHA.106.478230. Epub 2007 Apr 26.
4
Cost and Utility Estimates per Modified Rankin Scale Score up to 2 Years Post Stroke: Data to Inform Economic Evaluations From a Societal Perspective.成本和效用估计每修改后的 Rankin 量表评分高达 2 年卒中后:数据从社会角度告知经济评价。
Value Health. 2024 Apr;27(4):441-448. doi: 10.1016/j.jval.2024.01.001. Epub 2024 Jan 18.
5
Utility-Weighted Modified Rankin Scale Scores for the Assessment of Stroke Outcome: Pooled Analysis of 20 000+ Patients.效用加权改良 Rankin 量表评分用于评估脑卒中结局:20000 余例患者的汇总分析。
Stroke. 2020 Aug;51(8):2411-2417. doi: 10.1161/STROKEAHA.119.028523. Epub 2020 Jul 9.
6
Utilities Estimated from PROMIS Scales for Cost-Effectiveness Analyses in Stroke.基于 PROMIS 量表的脑卒中成本效益分析效用值估算。
Med Decis Making. 2023 Aug;43(6):704-718. doi: 10.1177/0272989X231182446. Epub 2023 Jul 4.
7
The feasibility, repeatability, validity and responsiveness of the EQ-5D-3L in Krio for patients with stroke in Sierra Leone.塞拉利昂中风患者克里奥语版 EQ-5D-3L 的可行性、可重复性、有效性和反应度。
Health Qual Life Outcomes. 2024 Mar 28;22(1):29. doi: 10.1186/s12955-024-02246-x.
8
Validation of the simplified modified Rankin scale for stroke trials: Experience from the ENCHANTED alteplase-dose arm.用于卒中试验的简化改良Rankin量表的验证:来自ENCHANTED阿替普酶剂量组的经验
Int J Stroke. 2021 Feb;16(2):222-228. doi: 10.1177/1747493019897858. Epub 2020 Jan 22.
9
Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke: The ENCHANTED Trial.急性缺血性脑卒中患者功能结局质量的种族及其他决定因素:ENCHANTED 试验。
Stroke. 2020 Feb;51(2):588-593. doi: 10.1161/STROKEAHA.119.027639. Epub 2019 Dec 11.
10
Can EQ-5D-3L utility values of low back pain patients be validly predicted by the Oswestry Disability Index for use in cost-effectiveness analyses?腰痛患者的 EQ-5D-3L 效用值能否通过 Oswestry 残疾指数有效预测,以用于成本效益分析?
Qual Life Res. 2022 Jul;31(7):2153-2165. doi: 10.1007/s11136-022-03082-6. Epub 2022 Jan 17.

引用本文的文献

1
Mobile stroke units services in Germany: A cost-effectiveness modeling perspective on catchment zones, operating modes, and staffing.德国的移动卒中单元服务:关于集水区、运营模式和人员配置的成本效益建模视角
Eur J Neurol. 2025 Jan;32(1):e16514. doi: 10.1111/ene.16514. Epub 2024 Nov 6.
2
Cost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo - the CHIMES & CHIMES-E studies.MLC601 在卒中后功能恢复方面的成本效益优于安慰剂——CHIMES 和 CHIMES-E 研究。
BMC Health Serv Res. 2024 Sep 27;24(1):1127. doi: 10.1186/s12913-024-11618-4.
3
Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.缺血性卒中和短暂性脑缺血发作后氯吡格雷抵抗基因型检测的临床和成本效益:系统评价和经济模型。
Health Technol Assess. 2024 Sep;28(57):1-194. doi: 10.3310/PWCB4016.
4
Cost-effectiveness of endovascular thrombectomy for acute ischemic stroke with established large infarct in Germany: a decision tree and Markov model.德国针对已形成大面积梗死的急性缺血性卒中进行血管内血栓切除术的成本效益:决策树和马尔可夫模型
J Neurointerv Surg. 2025 Jun 16;17(7):683-690. doi: 10.1136/jnis-2024-021837.
5
Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysis.软件采用人工智能衍生算法分析疑似急性脑卒中患者的 CT 脑扫描:系统评价和成本效益分析。
Health Technol Assess. 2024 Mar;28(11):1-204. doi: 10.3310/RDPA1487.
6
International Systematic Review of Utility Values Associated with Cardiovascular Disease and Reflections on Selecting Evidence for a UK Decision-Analytic Model.国际心血管疾病效用值系统评价及对英国决策分析模型中证据选择的思考。
Med Decis Making. 2024 Feb;44(2):217-234. doi: 10.1177/0272989X231214782. Epub 2024 Jan 4.
7
A systematic review and meta-analysis of health utility values among patients with ischemic stroke.缺血性中风患者健康效用值的系统评价与荟萃分析。
Front Neurol. 2023 Sep 5;14:1219679. doi: 10.3389/fneur.2023.1219679. eCollection 2023.
8
Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke.替奈普酶与阿替普酶治疗急性缺血性脑卒中的成本效果分析。
Eur Stroke J. 2023 Sep;8(3):638-646. doi: 10.1177/23969873231174943. Epub 2023 May 19.
9
Cost-utility of direct transfer to angiography suite (DTAS) bypassing conventional imaging for patients with acute ischemic stroke in Spain: results from the ANGIOCAT trial.西班牙急性缺血性脑卒中患者直接转入血管造影室(DTAS)绕过常规影像学检查的成本-效用研究:来自 ANGIOCAT 试验的结果。
J Neurointerv Surg. 2024 Jan 12;16(2):138-142. doi: 10.1136/jnis-2023-020275.
10
Cost-effectiveness of rhythm control strategy: Ablation versus antiarrhythmic drugs for treating atrial fibrillation in Korea based on real-world data.节律控制策略的成本效益:基于真实世界数据比较韩国房颤治疗中导管消融与抗心律失常药物的效果
Front Cardiovasc Med. 2023 Jan 24;10:1062578. doi: 10.3389/fcvm.2023.1062578. eCollection 2023.

本文引用的文献

1
Chinese time trade-off values for EQ-5D health states.中国人群 EQ-5D 量表健康状态时间权衡值。
Value Health. 2014 Jul;17(5):597-604. doi: 10.1016/j.jval.2014.05.007. Epub 2014 Jul 23.
2
Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states.新加坡EQ-5D-3L健康状态的估值:80种经验观察到的健康状态的时间权衡价值建模
Pharmacoeconomics. 2014 May;32(5):495-507. doi: 10.1007/s40273-014-0142-1.
3
Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010.1990-2010 年全球及各区域卒中负担变化:来自 2010 年全球疾病负担研究的结果。
Lancet. 2014 Jan 18;383(9913):245-54. doi: 10.1016/s0140-6736(13)61953-4.
4
Very low quality of life after acute stroke: data from the Efficacy of Nitric Oxide in Stroke trial.急性脑卒中后生活质量极低:来自卒中应用一氧化氮疗效试验的数据。
Stroke. 2013 Dec;44(12):3458-62. doi: 10.1161/STROKEAHA.113.002201. Epub 2013 Oct 22.
5
Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.用于 NICE 健康技术评估的 EQ-5D 效用值映射。
Value Health. 2013 Jan-Feb;16(1):202-10. doi: 10.1016/j.jval.2012.10.010.
6
Testing for differential item functioning within the EQ-5D.在 EQ-5D 中进行差异项目功能测试。
Med Decis Making. 2013 Feb;33(2):252-60. doi: 10.1177/0272989X12465016. Epub 2012 Nov 26.
7
Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses.开发、扩展和利用中风临床试验资源进行新的探索性分析。
Int J Stroke. 2012 Feb;7(2):133-8. doi: 10.1111/j.1747-4949.2011.00735.x.
8
Time trade-off derived EQ-5D weights for Australia.澳大利亚时间权衡法衍生的 EQ-5D 权重。
Value Health. 2011 Sep-Oct;14(6):928-36. doi: 10.1016/j.jval.2011.04.009. Epub 2011 Aug 4.
9
Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.基于 OM8-30 中耳炎问卷的应答情况进行健康效用值的映射分析估计。
Qual Life Res. 2010 Feb;19(1):65-80. doi: 10.1007/s11136-009-9558-z. Epub 2009 Nov 26.
10
Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome.将改良 Rankin 量表(mRS)测量值映射到通用欧洲五维健康量表(EQ-5D)健康结局。
Med Decis Making. 2010 May-Jun;30(3):341-54. doi: 10.1177/0272989X09349961. Epub 2009 Oct 26.

中风中的依赖性与健康效用:为成本效益分析提供信息的数据。

Dependency and health utilities in stroke: Data to inform cost-effectiveness analyses.

作者信息

Ali Myzoon, MacIsaac Rachael, Quinn Terence J, Bath Philip M, Veenstra David L, Xu Yaping, Brady Marian C, Patel Anita, Lees Kennedy R

机构信息

Institutes of Cardiovascular and Medical Sciences, Queen Elizabeth University Hospital, Glasgow, UK.

Institutes of Cardiovascular and Medical Sciences, Glasgow Royal Infirmary, Glasgow, UK.

出版信息

Eur Stroke J. 2017 Mar;2(1):70-76. doi: 10.1177/2396987316683780. Epub 2017 Mar 1.

DOI:10.1177/2396987316683780
PMID:30009266
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6027777/
Abstract

INTRODUCTION

Health utilities (HU) assign preference weights to specific health states and are required for cost-effectiveness analyses. Existing HU for stroke inadequately reflect the spectrum of post-stroke disability. Using international stroke trial data, we calculated HU stratified by disability to improve precision in future cost-effectiveness analyses.

MATERIALS AND METHODS

We used European Quality of Life Score (EQ-5D-3L) data from the Virtual International Stroke Trials Archive (VISTA) to calculate HU, stratified by modified Rankin Scale scores (mRS) at 3 months. We applied published value sets to generate HU, and validated these using ordinary least squares regression, adjusting for age and baseline National Institutes of Health Stroke Scale (NIHSS) scores.

RESULTS

We included 3858 patients with acute ischemic stroke in our analysis (mean age: 67.5 ± 12.5, baseline NIHSS: 12 ± 5). We derived HU using value sets from 13 countries and observed significant international variation in HU distributions (Wilcoxon signed-rank test  < 0.0001, compared with UK values). For mRS = 0, mean HU ranged from 0.88 to 0.95; for mRS = 5, mean HU ranged from -0.48 to 0.22. OLS regression generated comparable HU (for mRS = 0, HU ranged from 0.9 to 0.95; for mRS = 5, HU ranged from -0.33 to 0.15). Patients' mRS scores at 3 months accounted for 65-71% of variation in the generated HU.

CONCLUSION

We have generated HU stratified by dependency level, using a common trial endpoint, and describing expected variability when applying diverse value sets to an international population. These will improve future cost-effectiveness analyses. However, care should be taken to select appropriate value sets.

摘要

引言

健康效用(HU)为特定健康状态赋予偏好权重,是成本效益分析所必需的。现有的中风健康效用未能充分反映中风后残疾的范围。利用国际中风试验数据,我们计算了按残疾分层的健康效用,以提高未来成本效益分析的精度。

材料与方法

我们使用虚拟国际中风试验档案库(VISTA)中的欧洲生活质量评分(EQ-5D-3L)数据来计算健康效用,按3个月时的改良Rankin量表评分(mRS)分层。我们应用已发表的价值集来生成健康效用,并使用普通最小二乘法回归进行验证,同时对年龄和基线美国国立卫生研究院卒中量表(NIHSS)评分进行调整。

结果

我们的分析纳入了3858例急性缺血性中风患者(平均年龄:67.5±12.5,基线NIHSS:12±5)。我们使用来自13个国家的价值集得出健康效用,并观察到健康效用分布存在显著的国际差异(Wilcoxon符号秩检验<0.0001,与英国值相比)。对于mRS = 0,平均健康效用范围为0.88至0.95;对于mRS = 5,平均健康效用范围为 -0.48至0.22。普通最小二乘法回归得出的健康效用相当(对于mRS = 0,健康效用范围为0.9至0.95;对于mRS = 5,健康效用范围为 -0.33至0.15)。患者3个月时的mRS评分占所生成健康效用变异的65 - 71%。

结论

我们使用共同的试验终点,生成了按依赖程度分层的健康效用,并描述了将不同价值集应用于国际人群时预期的变异性。这些将改善未来的成本效益分析。然而,应谨慎选择合适的价值集。